BTSG BrightSpring Health Services, Inc.

Option Care Health (OPCH) is back in focus after fresh commentary compared its home and alternate site infusion business with BrightSpring Health Services, highlighting how both could benefit as complex treatments continue shifting into lower cost home settings. Recent trading tells a mixed story. Option Care Health’s share price is up 8.41% over the past 90 days but down 29.25% year to date, while the 1 year total shareholder return has declined 17.83%, which may hint at fading momentum...

BrightSpring's faster growth, pharmacy and provider-service expansion, and improving margins contrast with OPCH's slower growth and chronic-therapy pressures.

BrightSpring Health Services (NASDAQ:BTSG) outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for comple

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the ones that make you life-changing money.

BTSG's stronger cash flow and lower leverage could give it more flexibility to pursue acquisitions and support future growth.

RDVT, BTSG and THC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 24th, 2026.

BrightSpring Health Services (BTSG) is back on investor radar after Carillon Eagle Small Cap Growth Fund highlighted the healthcare provider in its second quarter 2026 letter, citing revenue and adjusted EBITDA ahead of IPO expectations. Despite the upbeat fund commentary, BrightSpring Health Services has hit a softer patch on the screen, with the share price at US$56.55 after a 1-day share price return of 1.24% but a 90-day share price return that has declined 16.36%. The year-to-date share...

Momentum stocks Centene, BrightSpring Health Services and Delek US show strong annual gains despite recent weekly pullbacks.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the “Carillon Eagle Small Cap Growth Fund”. The letter can be downloaded here. Small-cap stocks rallied broadly in the second quarter, with the Russell 2000 Growth Index (+25.71%) outpacing Value +17.24%). Information Technology (+46.79%) led all sectors, supported by solid gains […]

BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.

BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.

Cash-generating companies often have the flexibility to invest, return capital to shareholders, or navigate downturns. The best of these businesses not only accumulate cash but deploy it strategically for growth.

BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.

BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.

BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.

NVDA's 63.7% net profit margin and 93.3% expected earnings growth put it among three profitable stocks positioned for market volatility.

William Blair’s latest Conviction List is putting three under-the-radar stocks, BJ’s Restaurants, APi Group, and BrightSpring Health Services, in the spotlight.

William Blair Names 8 New Stock Picks: AI, Defense and Healthcare Stand Out

BrightSpring Health Services (BTSG) is back in focus after recent reports highlighted strong quarterly performance, long term revenue growth and an approximately 9% uplift in earnings expectations that coincided with a Zacks Rank #1 rating. The share price tells a similar story of strong interest in BrightSpring Health Services, with a year-to-date share price return of 58.59% and a 1-year total shareholder return of 156.64%. This comes even after a 15.95% decline over the past 30 days from...

What a fantastic six months it’s been for BrightSpring Health Services. Shares of the company have skyrocketed 47.6%, hitting $61.14. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.

BTSG, OPHC, HRTG, UMC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on August 26th, 2026.

CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.

Sandisk, Celestica and BrightSpring have been highlighted in this Screen of The Week article.

Sandisk, Celestica and BrightSpring rank among profitable stocks, with strong net income ratios and earnings growth supporting upside.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the senior health, home health & hospice industry, including BrightSpring Health Services (NASDAQ:BTSG) and its peers.

CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.

BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 27.5% over the past six months, topping the S&P 500 by 16.2 percentage points.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

BrightSpring Health Services (BTSG) was in focus after releasing second quarter 2026 results on July 31, alongside updated full year revenue guidance that shaped investor expectations for the rest of the year. See our latest analysis for BrightSpring Health Services. BrightSpring Health Services shares have been volatile in recent weeks, with a 3.09% 1 day share price gain following earnings offset by a 14.30% decline over 30 days. However, the year to date share price return of 55.42% and 1...

BrightSpring Health Services stock has delivered a very strong 166.5% gain over the past year, yet recent pullbacks and a mixed valuation score leave investors weighing how much of the good news is already reflected in the price. Over the last 12 months the share price is up 166.5%, which signals that expectations for BrightSpring Health Services are already running high. Stronger revenue momentum and growth in pharmacy and care services can support a premium, while concerns around profit...

BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.

In today’s market, large companies dominate the landscape and grow their leads by acquiring smaller competitors - a trend that will accelerate with the Trump administration. However, some mid-sized players will continue thriving because they’ve carved durable niches for themselves.

BrightSpring Health Services delivered revenue and adjusted profit above Wall Street expectations in Q2, but the market’s negative reaction reflected concerns about underlying headwinds. Management attributed strong year-over-year growth to continued expansion in its Specialty and Infusion pharmacy business, alongside disciplined operational execution and efficiency gains from technology investments. CEO Jon Rousseau detailed that "our Specialty and Infusion business delivered revenue growth of

CEO Rousseau discusses specialty pharmacy expansion and integration of recent acquisitions.

BTSG Health Services raises its 2026 outlook as Pharmacy and Provider growth, margin gains and lower leverage strengthen operating momentum.

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

BJ's, Patterson-UTI Energy and BrightSpring have been highlighted in this Screen of The Week article.

Micron, BrightSpring Health and Custom Truck One Source combine strong profitability with earnings growth. See why they stand out in August.

BJ's Restaurants, Patterson-UTI Energy and BrightSpring Health Services stand out after recent broker upgrades, backed by projected solid 2026 earnings growth.

Investors need to pay close attention to BTSG stock based on the movements in the options market lately.

BrightSpring beat second-quarter estimates and raised its 2026 outlook as specialty, infusion and home health growth lifted margins and EBITDA.

BrightSpring's broad-based growth and margin gains strengthen its outlook, but a premium valuation leaves little room for execution missteps.

BrightSpring's 18.1% weekly slide clashes with strong growth and raised guidance as valuation, policy and integration risks test the rebound case.

In the second quarter of 2026, BrightSpring Health Services reported revenue of US$3.87 billion and net income of US$84.29 million, with earnings per share rising sharply versus a year earlier and six‑month results also materially higher. Alongside these results, the company raised its full‑year 2026 revenue guidance to a range of US$15.10 billion to US$15.43 billion, highlighting management confidence even as investors weigh what this means for profit margins and growth expectations. With...

BTSG's Q2 earnings and revenues beat estimates as pharmacy and provider growth drive margin gains and a higher 2026 outlook.

Moby summary of BrightSpring Health Services, Inc. Common Stock's Q2 2026 earnings call